Are myelodysplastic syndromes ready for venetoclax? Exploring future potential and considerations

Expert Rev Hematol. 2021 Sep;14(9):789-793. doi: 10.1080/17474086.2021.1968822. Epub 2021 Aug 26.

Authors

Judith S Hecker¹, Lavinia Pachzelt¹, Katharina S Götze¹

Affiliation

¹ Department of Medicine III, Technische Universität München, Klinikum rechts der Isar, Munich, Germany.

PMID: 34405747
DOI: 10.1080/17474086.2021.1968822

No abstract available

Keywords: Apoptosis; BCL-2; azacitidine; myelodysplastic syndromes; venetoclax.

Publication types

Editorial

MeSH terms

Azacitidine
Bridged Bicyclo Compounds, Heterocyclic / therapeutic use
Humans
Leukemia, Myeloid, Acute*
Myelodysplastic Syndromes* / drug therapy
Sulfonamides / therapeutic use

Substances

Bridged Bicyclo Compounds, Heterocyclic
Sulfonamides
Azacitidine
venetoclax